Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endologix Inc (ELGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 621,146
  • Shares Outstanding, K 82,930
  • Annual Sales, $ 192,930 K
  • Annual Income, $ -154,680 K
  • 36-Month Beta 0.79
  • Price/Sales 3.21
  • Price/Cash Flow 0.00
  • Price/Book 5.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.21 +20.61%
on 04/13/17
7.53 -0.53%
on 04/27/17
+0.41 (+5.79%)
since 03/28/17
3-Month
5.58 +34.23%
on 02/23/17
7.53 -0.53%
on 04/27/17
+0.74 (+10.96%)
since 01/27/17
52-Week
4.78 +56.69%
on 12/28/16
14.49 -48.31%
on 07/12/16
-3.99 (-34.76%)
since 04/28/16

Most Recent Stories

More News
Endologix, Inc. to Host an Investor Conference Call to Discuss its Nellix(R) Endovascular Aneurysm Sealing System Presentation at the Society of Vascular Surgery Annual Meeting on June 3, 2017

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter's submission "Refinement of the IFU for...

ELGX : 7.49 (+0.27%)
Watch for Endologix to Potentially Rebound After Falling 2.38% Yesterday

Endologix (NASDAQ:ELGX) traded in a range yesterday that spanned from a low of $6.49 to a high of $6.76. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $6.62 on...

ELGX : 7.49 (+0.27%)
Deerfield Management Company Invests $170 Million to Advance Aortic Disorder Treatment

Deerfield Management Company announced today that it has committed to provide up to $170 million to Endologix, Inc. in a combination of senior secured notes and a working capital facility.

ELGX : 7.49 (+0.27%)
Endologix Enters into $170 Million Credit Facility with Deerfield Management

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"),...

ELGX : 7.49 (+0.27%)
Endologix, Inc. Announces Enrollment of First Patients in ELEVATE IDE Clinical Study

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the Expanding Patient...

ELGX : 7.49 (+0.27%)
DEADLINE TODAY FOR ELGX INVESTORS: Lundin Law PC Announces Securities Class Action Lawsuit Against Endologix, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / March 6, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endologix, Inc. ("Endologix" or the "Company") (NASDAQ: ELGX) concerning...

ELGX : 7.49 (+0.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endologix, Inc. of Class Action Lawsuit and Upcoming Deadline - ELGX

NEW YORK, NY / ACCESSWIRE / March 3, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Endologix, Inc. ("Endologix" or the "Company") (NASDAQ: ELGX) and certain of its officers....

ELGX : 7.49 (+0.27%)
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endologix Inc. (ELGX) and Lead Plaintiff Deadline: March 6, 2017

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Endologix Inc. ("Endologix" or the "Company") (NASDAQ:ELGX) and certain of...

ELGX : 7.49 (+0.27%)
SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Endologix, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 27, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Endologix, Inc. ("Endologix" or the "Company") (NASDAQ: ELGX) concerning...

ELGX : 7.49 (+0.27%)
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 6, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Endologix Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central...

ELGX : 7.49 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Support & Resistance

2nd Resistance Point 7.61
1st Resistance Point 7.55
Last Price 7.49
1st Support Level 7.40
2nd Support Level 7.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.